The genetic characterization of urothelial tumor disease has brought to light important information about the biology of the disease. The evaluation of molecular DNA markers on tumor tissue could be an approach able to provide important information on the possible aggressiveness of the disease and the sensitivity/resistance profile to drugs commonly adopted in the advanced stage. The main objective of this study is to identify specific molecular profiles from DNA capable of predicting the clinical course of the disease and the possible sensitivity/resistance of the disease to systemic treatments
None
aged > 18 years
suffering from locally advanced or metastatic urothelial neoplasia
with the availability of tumor tissue obtained during surgery on a primary tumor or metastasis or during a diagnostic biopsy.
Patients diagnosed with urothelial cancer
Cohort
Other
Not listed
evaluation of the prognostic and predictive role of response to systemic therapy of specific molecular markers extracted from tumor DNA.
The study involves the analysis by massive sequencing (Next Generation Sequencing) of molecular profiles of tumor DNA extracted from tumor tissue obtained during surgery (on primary and/or metastases) or diagnostic biopsy performed as part of the normal clinical care pathway. These data will be integrated with information relating to anamnestic data and clinical, laboratory and instrumental parameters of patients with urothelial neoplasia
molecular profiles predictive of response/resistance to chemotherapy, immune-checkpoint inhibitors, target therapy
Search for molecular profiles predictive of response/resistance to chemotherapy, immune-checkpoint inhibitors, target therapy
Click on the lead sponsor to view all of their trials.
